ENDPOINTS

Ahead of FDA decision, Alnylam faces the big question: ...

Despite pioneering RNAi drug development and getting four therapies approved, Al...

Cargo Therapeutics scraps R&D pipeline, axes bulk of wo...

As Cargo Therapeutics looks for a permanent solution to its troubles, the biotec...

Regenxbio shares new Duchenne gene therapy data ahead o...

Regenxbio has biomarker data on the first patient younger than 4 years old dosed...

Pfizer fully exits Haleon in $3.3B stake sale

Pfizer will get about $3.3 billion from its final stake sale in Haleon, accordin...

Immunovant will not take rare disease drug to regulator...

Immunovant will not seek approval for its candidate for the autoimmune disorder ...

Immunovant will not take rare disease drug to regulator...

Immunovant will not seek approval for its candidate for the autoimmune disorder ...

Roche inks $1B+ biobucks deal with Oxford BioTherapeuti...

Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new...

Servier pays $70M upfront for Black Diamond’s RAS- and ...

Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer ...

Flagship's Ampersand gets Eli Lilly's support in $65M S...

Ampersand Biomedicines, a biotech working on medicines "similar in principle" to...

Stem cell company bit.bio lays off quarter of staff

The British stem cell company bit.bio has reduced its workforce by 25%, impactin...

HHS extends administrative leave for probationary worke...

Following a court order, HHS won't fire more than 2,800 probationary employees i...

Novartis revamps commercial strategy as Entresto patent...

With its decadelong US patent for Entresto set to expire in a few months, Novart...

Updated: Novartis revamps cardiovascular commercial str...

With its decade-long US patent for Entresto set to come to an end in a few month...

Empress Therapeutics confirms layoffs; Nanobiotix amend...

Plus, news about Pyxis Oncology, Kiromic BioPharma, TC BioPharm, EnteroBiotix, L...

Stoke CEO Ed Kaye to depart shortly after inking Biogen...

In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the compan...

Sixteen-year-old dies after receiving Sarepta’s Duchenn...

A teenage boy who received Sarepta’s Duchenne muscular dystrophy gene therapy El...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.